A new hope for MDS patients: could this drug cut blood transfusions?
NCT ID NCT07752121
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This study looks at whether luspatercept, a drug given as first-line treatment, can help adults with low-risk myelodysplastic neoplasms (MDS) who need regular red blood cell transfusions. Researchers will follow about 190 participants for up to 2 years to see how often they achieve periods without transfusions, changes in hemoglobin levels, and quality of life. The study observes routine medical care in Germany, providing real-world insights into the drug's effectiveness and safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- luspatercept
- What this could lead to
- If successful, this could show that luspatercept helps people with low-risk MDS go longer without needing blood transfusions, improving their quality of life.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. The drug may not work for everyone, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Universitätsmedizin der Johannes Gutenberg-Univ. III. Med. Klinik Hämatologie/Onkologie
Mainz, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.